Chikungunya vaccine successful in clinical trial
The Austrian biotech company Themis Bioscience GmbH in collaboration with the Institut Pasteur (Paris, France) has developed a prophylactic vaccine against chikungunya. The vaccine appears to be safe, and produced an immune response that researchers suspect would protect people against infection.
The Vienna-based biotech company Themis Bioscience GmbH (‘Themis’) has received final results of a phase 1 clinical study of its prophylactic Chikungunya fever vaccine.
The study was carried out on 42 subjects at the Department of Clinical Pharmacology of the Vienna General Hospital (Allgemeines Krankenhaus der Stadt Wien) and confirms the previous interim results: The candidate not only proved to be well tolerated and safe, but also exhibited the required immune response in the form of neutralizing antibodies in all vaccinated subjects. Remarkably, the immune response was clearly dose-dependent with even the lowest dose being effective.
Read more Jamaica News